

## Special Issue

# Emerging Paradigms in Insulin Resistance

### Message from the Guest Editor

Insulin resistance is defined as defective insulin action in its target tissues. There are many discrete routes to the onset of peripheral insulin resistance, e.g., obesity, chronic glucocorticoid excess, lipodystrophy, etc.; therefore, much remains to be determined regarding the underlying pathology of insulin resistance and tissue specific mechanisms. This Special Issue of *Biomedicines* is entitled “Emerging Paradigms in Insulin Resistance”. The topics covered in the Special Issue include but are not limited to original research articles that identify novel pathways and factors involved in the development of insulin resistance, emerging technological advances or tools in the study of insulin resistance, and novel genetic models developed to study insulin resistance and associated metabolic pathologies. We also invite the submission of review articles that provide a comprehensive overview of recent innovative advances in studying insulin resistance and its consequent metabolic alterations.

---

### Guest Editor

Dr. Susan J. Burke  
Pennington Biomedical Research Center, Baton Rouge, LA, USA

---

### Deadline for manuscript submissions

closed (30 November 2021)



# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/53893](http://mdpi.com/si/53893)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
biomedicines@mdpi.com

[mdpi.com/journal/  
biomedicines](http://mdpi.com/journal/biomedicines)





# Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](http://mdpi.com/journal/biomedicines)

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

